Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Profitability
This table compares Atea Pharmaceuticals and Tenaya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atea Pharmaceuticals | N/A | -57.01% | -51.49% |
| Tenaya Therapeutics | N/A | -80.56% | -65.21% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Atea Pharmaceuticals and Tenaya Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atea Pharmaceuticals | 1 | 0 | 0 | 1 | 2.50 |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Insider and Institutional Ownership
86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Atea Pharmaceuticals and Tenaya Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atea Pharmaceuticals | N/A | N/A | -$158.35 million | ($2.11) | -2.31 |
| Tenaya Therapeutics | $225,000.00 | 787.95 | -$90.60 million | ($0.47) | -1.74 |
Tenaya Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Atea Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500.
Summary
Tenaya Therapeutics beats Atea Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
